A 24-Week, Multicenter, Randomized, Parallel-group, Open-label, Active Controlled Phase IV Study to Assess the Efficacy and Safety of Dapagliflozin as Monotherapy Compared With Acarbose in Drug-Naive Patients With Type 2 Diabetes Mellitus (T2DM) in China
Phase of Trial: Phase IV
Latest Information Update: 11 Mar 2019
Price : $35 *
At a glance
- Drugs Dapagliflozin (Primary) ; Acarbose
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors AstraZeneca
- 11 Mar 2019 Last checked against ClinicalTrials.gov record
- 07 Mar 2019 Planned End Date changed from 31 Aug 2019 to 31 Aug 2020.
- 07 Mar 2019 Planned primary completion date changed from 31 Aug 2019 to 31 Aug 2020.